NCNA NuCana plc

5.03
-0.08  -1%
Previous Close 5.11
Open 5.06
Price To Book 1.77
Market Cap 163,402,978
Shares 32,456,000
Volume 3,820
Short Ratio
Av. Daily Volume 53,665
Stock charts supplied by TradingView

NewsSee all news

  1. NuCana Announces First Patients Dosed in Both US and Europe in Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer

    Global NuTide:121 Study Is Enrolling up to 828 Patients and Comparing Acelarin plus Cisplatin to Gemcitabine plus Cisplatin NuTide:121 Trials-in-Progress Poster Presented at ASCO-GI SAN FRANCISCO, Jan. 27, 2020

  2. NuCana to Participate in the Piper Jaffray 31st Annual Healthcare Conference

    EDINBURGH, United Kingdom, Nov. 26, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Don Munoz, Chief Financial Officer, will host one-on-one meetings at the Piper Jaffray 31st Annual Healthcare

  3. NuCana to Present at the Jefferies 2019 London Healthcare Conference

    EDINBURGH, United Kingdom, Nov. 14, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host

  4. NuCana Reports Third Quarter 2019 Financial Results and Provides Business Update

    Opens Phase III Global Biliary Tract Cancer Study (NuTide:121) with Potential for Accelerated Approval Filing Focusing Resources on Key Value-Driving Programs of Biliary Tract Cancer and Colorectal Cancer Cash and Cash

  5. NuCana Presents Data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    NUC-3373: Favorable Pharmacokinetic Profile Demonstrated NUC-7738: Multiple Anti-Cancer Mechanisms of Action Identified, including Inhibition of the mTOR Pathway BOSTON, Oct. 29, 2019 (GLOBE NEWSWIRE) -- NuCana plc

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 dosing has commenced - January 27, 2020.
NUC-1031 (Acelarin)
Front-Line Treatment of Advanced Biliary Tract Cancer
Phase 1 initial data due 2020.
NUC-3373
Solid tumors
Phase 3 enrolment suspended due to futility - August 20, 2019.
NUC-1031 (Acelarin)
Pancreatic cancer
Phase 2 (Part 1) data due 1H 2020. However, Part 2 portion of trial will not be initiated.
NUC-1031 (Acelarin)
Platinum-sensitive ovarian cancer
Phase 1b data due 2020.
NUC-3373
Colorectal Cancer
Phase 1 data due 2020.
NUC-7738
Solid tumors

Latest News

  1. NuCana Announces First Patients Dosed in Both US and Europe in Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer

    Global NuTide:121 Study Is Enrolling up to 828 Patients and Comparing Acelarin plus Cisplatin to Gemcitabine plus Cisplatin NuTide:121 Trials-in-Progress Poster Presented at ASCO-GI SAN FRANCISCO, Jan. 27, 2020

  2. NuCana to Participate in the Piper Jaffray 31st Annual Healthcare Conference

    EDINBURGH, United Kingdom, Nov. 26, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Don Munoz, Chief Financial Officer, will host one-on-one meetings at the Piper Jaffray 31st Annual Healthcare

  3. NuCana to Present at the Jefferies 2019 London Healthcare Conference

    EDINBURGH, United Kingdom, Nov. 14, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host

  4. NuCana Reports Third Quarter 2019 Financial Results and Provides Business Update

    Opens Phase III Global Biliary Tract Cancer Study (NuTide:121) with Potential for Accelerated Approval Filing Focusing Resources on Key Value-Driving Programs of Biliary Tract Cancer and Colorectal Cancer Cash and Cash

  5. NuCana Presents Data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    NUC-3373: Favorable Pharmacokinetic Profile Demonstrated NUC-7738: Multiple Anti-Cancer Mechanisms of Action Identified, including Inhibition of the mTOR Pathway BOSTON, Oct. 29, 2019 (GLOBE NEWSWIRE) -- NuCana plc

  6. NuCana to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

    EDINBURGH, United Kingdom, Aug. 29, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host

  7. NuCana to Participate in Citi's 14th Annual Biotech Conference

    EDINBURGH, United Kingdom, Aug. 27, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host one-on-one meetings